This article was originally published in Start Up
High-tech discovery methods so broadly embraced over the past decade haven't delivered expected gains in productivity. Phenomix Corp. thinks it will fare better by harnessing mouse models of disease, randomly mutagenizing genes, checking the resulting phenotypes for beneficial changes then tracking back to the gene.
You may also be interested in...
The process of hunting for drugs is now markedly different than it was a few decades ago, partly because research organizations are much bigger and market pressures more intense. Technology has catalyzed the biggest shifts, decreasing the role of individuals and putting more emphasis on method than conceptualization. But the high-tech methods haven't been as productive as expected, and so research executives are increasingly considering which of the traditional ways might be worth recapturing.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.